Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease
Journal Title: The AAPS Journal - Year 2009, Vol 11, Issue 3
Abstract
Parkinson’s disease is an age-related degenerative disorder of the central nervous system that often impairs the sufferer’s motor skills and speech, as well as other functions. Symptoms can include tremor, stiffness, slowness of movement, and impaired balance. An estimated four million people worldwide suffer from the disease, which usually affects people over the age of 60. Presently, there is no precedent for approving any drug as having a modifying effect (i.e., slowing or delaying) for disease progression of Parkinson’s disease. Clinical trial designs such as delayed start and withdrawal are being proposed to discern symptomatic and protective effects. The current work focused on understanding the features of delayed start design using prior knowledge from published and data submitted to US Food and Drug Administration (US FDA) as part of drug approval or protocol evaluation. Clinical trial simulations were conducted to evaluate the false-positive rate, power under a new statistical analysis methodology, and various scenarios leading to patient discontinuations from clinical trials. The outcome of this work is part of the ongoing discussion between the US FDA and the pharmaceutical industry on the standards required for demonstrating disease-modifying effect using delayed start design.
Authors and Affiliations
Venkatesh Atul Bhattaram, Ohidul Siddiqui, Leonard P. Kapcala, Jogarao V. S. Gobburu
Keywords
Related Articles
- EP ID EP681484
- DOI 10.1208/s12248-009-9123-2
- Views 89
- Downloads 0
Characterization of Microchannels Created by Metal Microneedles: Formation and Closure
Transdermal delivery of therapeutic agents for cosmetic therapy is limited to small and lipophilic molecules by the stratum corneum barrier. Microneedle technology overcomes this barrier and offers a minimally invasive a...
Safety of β2-Agonists in Asthma: Linking Mechanisms, Meta-Analyses and Regulatory Practice
An epidemic of asthma fatalities in the 1970s prompted a series of case-control studies which indicated that short acting β-agonists increased the risk of death. Subsequent mechanistic and pharmacodynamic studies...
Compartmental Tissue Distribution of Antibody Therapeutics: Experimental Approaches and Interpretations
Monoclonal antibodies have provided many validated and potential new therapeutic candidates for various diseases encompassing the realms of neurology, ophthalmology, immunology, and especially oncology. The mechanism of...
Chitosan and sodium alginate—Based bioadhesive vaginal tablets
Metronidazole was formulated in mucoadhesive vaginal tablets by directly compressing the natural cationic polymer chitosan, loosely cross-linked with glutaraldehyde, together with sodium alginate with or ine cellulose (M...
Stratification of Antibody-Positive Subjects by Antibody Level Reveals an Impact of Immunogenicity on Pharmacokinetics
The availability of highly sensitive immunoassays enables the detection of antidrug antibody (ADA) responses of various concentrations and affinities. The analysis of the impact of antibody status on drug pharmacokinetic...